Nephroprotektion durch die selektive VDR-Aktivierung mit Paricalcitol – Die VITAL-Studie

Literatur

• 1 Zeeuw D de, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.  Lancet. 2010;  376 1543-1551

01 Selective VITamin D receptor activator for Albuminuria Lowering